Coverage summary
Aardvark Labs Capital Research has covered Eli Lilly and Company (LLY) since August 8, 2025. The company is in the Healthcare sector. This page lists 6 reports: 6 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published October 30, 2026. That report moved the rating from Outperform to Hold. The rating has changed twice since coverage began.
Translations: 5 in Chinese.
The Excel model for LLY holds 22 quarters and 5 fiscal years of history and 10 quarters and 5 fiscal years of projections. It was last updated September 22, 2026.
Rating history
All LLY reports
Recap: Q3 2026
The Step-Down Never Came and Lilly Lifts Its Revenue Guide $5.5B, But a 10% Two-Day Run Prices It In. Downgrading to Hold
Recap: Q2 2026
$23.0B and a 370bp Margin Inflection, But Foundayo Undershoots and $2.8B of Deal Charges Swallow the EPS Raise — Maintaining Outperform, FV to $1,150–1,300
Recap: Q1 2026
Foundayo Launches, FY26 Guide Raised by $2B, Retatrutide Type-2 Diabetes Reads Through — Maintaining Outperform, FV $1,000–1,200
Recap: Q4 2025
$19.3B Quarter, Key Products +91%, FY26 Guide of $80–83B Revenue and a Pipeline That Just Doesn't Quit: Maintaining Outperform
Recap: Q3 2025
Six Phase III Orforglipron Trials Clear the Path to a 2026 Oral GLP-1 Launch, Mounjaro Internationals Accelerate, and the FY25 Guide Goes Up Again: Upgrading to Outperform
Recap: Q2 2025
Tirzepatide Franchise Compounds, FY Guide Raised $1.5B at Midpoint, Orforglipron ATTAIN-1 Reads Below the Injectable Bar — Initiating LLY at Hold